# OPTION: A Trial to Assess the Safety & Efficacy of MS1819 in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

> **NCT03746483** · PHASE2 · COMPLETED · sponsor: **Entero Therapeutics** · enrollment: 41 (actual)

## Conditions studied

- Exocrine Pancreatic Insufficiency (EPI)
- Cystic Fibrosis (CF)

## Interventions

- **DRUG:** MS1819
- **DRUG:** Porcine PERT

## Key facts

- **NCT ID:** NCT03746483
- **Lead sponsor:** Entero Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-10
- **Primary completion:** 2019-07-13
- **Final completion:** 2019-07-27
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2022-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03746483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03746483, "OPTION: A Trial to Assess the Safety & Efficacy of MS1819 in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03746483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*